The Food and Drug Administration recently issued a warning directed to healthcare professionals regarding Byetta (also known as exenatide), a medication used to treat individuals with type 2 diabetes produced by the pancreas and glucose made by the liver. There have been several reports of acute pancreatitis in patients who were taking Byetta. Several of the patients required hospitalization and some developed other serious complications including dehydration, renal failure and bowel obstruction. For this reason, the FDA has issued an advisory to medical providers to be alert for persistent abdominal pain, nausea and other symptoms of acute pancreatitis in patients using Byetta
Byetta is manufactured by Amylin Pharmaceuticals, Inc., and was approved for sale in the United States in April of 2005.
For more information on this subject, please refer to the section on Drugs, Medical Devices and Implants.